Literature DB >> 21261591

Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia.

Paul J Coleman1, Christopher D Cox, Anthony J Roecker.   

Abstract

Orexins are excitatory neuropeptides that have a critical role in maintaining wakefulness. Orexin receptor antagonists promote sleep in animals and humans. Indeed, small molecule orexin receptor antagonists have demonstrated clinical proof-of-concept in the treatment of primary insomnia. This review describes optimization of orexin receptor antagonists across diverse structural classes with a focus on how molecules were designed to optimize potency, physicochemical properties, pharmacokinetics, brain penetration, and in vivo activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21261591     DOI: 10.2174/1568026611109060696

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  7 in total

1.  Intramolecular fluorescence resonance energy transfer (FRET) sensors of the orexin OX1 and OX2 receptors identify slow kinetics of agonist activation.

Authors:  Tian-Rui Xu; Richard J Ward; John D Pediani; Graeme Milligan
Journal:  J Biol Chem       Date:  2012-03-02       Impact factor: 5.157

2.  Heteromultimerization of cannabinoid CB(1) receptor and orexin OX(1) receptor generates a unique complex in which both protomers are regulated by orexin A.

Authors:  Richard J Ward; John D Pediani; Graeme Milligan
Journal:  J Biol Chem       Date:  2011-09-09       Impact factor: 5.157

3.  Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs.

Authors:  Georgia McGaughey; Christopher I Bayly; Christopher D Cox; John D Schreier; Michael J Breslin; Michael Bogusky; Steve Pitzenberger; Richard Ball; Paul J Coleman
Journal:  J Comput Aided Mol Des       Date:  2014-02-01       Impact factor: 3.686

Review 4.  Orexin Receptor Antagonists and Insomnia.

Authors:  Xin Wu; Tao Xue; Zhouqing Chen; Zhong Wang; Gang Chen
Journal:  Curr Psychiatry Rep       Date:  2022-08-16       Impact factor: 8.081

Review 5.  Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.

Authors:  Ying Han; Kai Yuan; Yongbo Zheng; Lin Lu
Journal:  Neurosci Bull       Date:  2019-11-28       Impact factor: 5.203

6.  Manipulating the sleep-wake cycle and circadian rhythms to improve clinical management of major depression.

Authors:  Ian B Hickie; Sharon L Naismith; Rébecca Robillard; Elizabeth M Scott; Daniel F Hermens
Journal:  BMC Med       Date:  2013-03-22       Impact factor: 8.775

Review 7.  Targeted Orexin and Hypothalamic Neuropeptides for Migraine.

Authors:  Lauren C Strother; Anan Srikiatkhachorn; Weera Supronsinchai
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.